Rhinomaris, 0.05% spray 15 ml

Pharmacotherapeutic group
Antagonist – vasoconstrictor (alpha-adrenomimetic).
ATX code: R01AA07

Pharmacokinetics
Pharmacokinetics
Almost not absorbed by local administration. Plasma concentrations are so low as to be undetectable by modern analytical methods.

Pharmacological properties
Rhinomaris is a drug for intranasal application.

Xylometazoline has alpha-adrenomimetic action: it causes nasal mucosa blood vessels narrowing thus eliminating nasopharyngeal mucosa edema and hyperemia. Facilitates nasal breathing in rhinitis. In therapeutic concentrations it does not irritate nasal mucosa, does not cause hyperemia. The action starts a few minutes after application and lasts for 12 hours.

Sterilized sea water, contained in Rhinomaris, helps maintain normal physiologic condition of nasal mucosa, thinning of mucus and normalization of its production in bocalytic cells of nasal cavity mucosa.

Micronutrients improve the function of the atrial fibrillation epithelium, reducing adverse local reactions such as irritation and/or dryness of the nasopharyngeal mucosa.

Indications

Active ingredient

Composition

Composition in mg per 1 ml of the drug: 0.05%

The active ingredient

Xylometazoline hydrochloride 0.500

Excipients

Particulate matter/p>

Adriatic Sea water 251,000

Potassium dihydrophosphate 0.502

Purified water up to 1 ml

Special Instructions

Contraindications

Side effects

Overdose

Symptoms: worsening of side effects.

Treatment: conducting symptomatic therapy.

Pregnancy use

Similarities